Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

Phase 2

Not yet recruiting

• Conditions: Prostate Cancer Metastatic Disease
• Interventions: Drug: HRS-2189; Drug: HRS-5041

• Registration Number: NCT06738745
• Lead Sponsor: Fudan University

Brief Summary

Our study is aimed to evaluate the efficacy and safety of HRS-2189 combined with HRS-5041 in metastatic prostate cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-22
• Status Verified: 2024-12
• Study First Submitted QC: 2024-12-13
• Last Update Submitted: 2024-12-13
• Study First Posted: 2024-12-18
• Last Update Posted: 2024-12-18
• Study Start: 2024-12-31
• Primary Completion: 2027-01-31
• Study Completion: 2027-08-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 90

Inclusion Criteria

• 18 years to 80 years old (including boundary values), male subjects;
• ECOG PS Score: 0~1;
• Histologically or cytologically confirmed prostate adenocarcinoma, and no prior diagnosed as neuroendocrine carcinoma or small cell carcinoma;
• Disease progression when enrolled in the study;
• Confirmed metastatic disease by CT/MRI/99mTc radioactive bone scan;
• Subjects must have a life expectancy ≥ 3 months;
• Adequate organ function and marrow function (no corrective treatment within 14 days before first dose);
• Male subjects who have partner of childbearing potential should agree to take action of contraception and avoid to donate sperm;
• Willing and able to provide written informed consent and comply with the requirements and restrictions in the protocol.

Exclusion Criteria

• Known existence of CNS metastasis or meningeal metastasis, or known history of primary CNS tumor;
• Severe bone injury caused by bone metastasis identified by investigators, including uncontrolled severe bone pain, pathological bone fracture at the important part and spinal cord compression having occurred for the last 6 months or expected to occur in the near future;
• Existence of third space fluid that is not well controlled by effective methods, e.g. drainage;
• Has received antitumor surgery, radiotherapy, chemotherapy, targeted therapy, immunological therapy or attenuated live vaccine within 4 weeks before first dose of study therapy (6-week washout period for bicalutamide);
• Has been enrolled in other clinical trials within 4 weeks before first dose of study therapy;
• Use of other antitumor treatment during the study;
• Damage caused by any prior anti-tumor treatment has not recovered to ≤ grade 1 or criteria specified by this study (per NCI-CTCAE 5.0; except alopecia or other tolerable adverse events identified by investigators);
• Uncontrolled hypertension, or prior hypertensive crisis or history of hypertension;
• Existence of arterial/venous thrombotic event within 6 months before first dose, such as cerebrovascular accidents (including transient ischemic attack, cerebral haemorrhage and cerebral infarction), deep venous thrombosis and pulmonary embolism;
• Existence of one of multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea and bowel obstruction), or active gastrointestinal disease or other diseases which may obviously affect distribution of drug absorption, metabolism or excretion;
• Has active hepatitis B (HBsAg-positive and HBV DNA≥500 IU/mL), hepatitis C (positive for HCV antibody and HCV RNA above ULN) and hepatic cirrhosis;
• Has an active infection requiring antibiotics, antiviral or antifungal treatment, or pyrexia >38.5℃ of unknown origin during the screening period before first dose of study therapy (patients with pyrexia due to cancer could be enrolled determined by investigator);
• Subjects with innate or acquired immunodeficiency (such as HIV infection); Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation;
• Other malignancy within prior 3 years before first dose of study therapy, except curatively treated cancer, including radical therapy-treated skin basal cell carcinoma or skin squamous cell carcinoma, papillary thyroid carcinoma, or any type of in situ carcinoma with complete excision, such as in situ cancer of the cervix, ductal carcinoma in situ of breast;
• Hypersensitivity to study therapy or any of its excipients;
• Uncontrolled cardiovascular clinical symptom or disease within 6 months before first dose of study therapy;
• Other conditions that might influence the study and analysis of results in the opinion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
HRS-2189 + HRS-5041	HRS-2189	All subjects enrolled will receive HRS-2189 + HRS-5041 combination therapy.
HRS-2189 + HRS-5041	HRS-5041	All subjects enrolled will receive HRS-2189 + HRS-5041 combination therapy.

Primary Outcome Measures

Name	Time	Method
PSA50	up to 2 years	PSA50 is the percentage of evaluable patients with ≥50% decline in PSA level, measured at baseline and the time point of every 4 weeks in efficacy analysis set.

Secondary Outcome Measures

Name	Time	Method
PSA30	up to 2 years	PSA30 is the percentage of evaluable patients with ≥30% decline in PSA level measured at baseline and the time point of every 4 weeks in efficacy analysis set.
Time to PSA progression	up to 2 years	The definition is the time from the date of first dose until the date of first PSA progression or death (by any cause in the absence of progression). PSA progression is per PCWG3 criteria and newest version of CSCO guideline as follows: 1) if PSA level declines from baseline, PSA level is ≥25% increase from baseline and ≥1 ng/ml, which needs to be confirmed after at least 4 weeks; 2) if PSA level has not declined from baseline, PSA level is ≥25% increase from baseline and ≥1 ng/ml after at least 12 weeks from the date of first dose.
ORR by investigator	up to 2 years	ORR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR (complete response) or PR (partial response) per RECIST v1.1, and measured at baseline and the time point of every 8 weeks in first 16 weeks, at the time point of every 12 weeks after first 16 weeks.
DCR by investigator	up to 2 years	DCR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR (complete response), PR (partial response) or SD (stable disease) per RECIST v1.1, and measured at baseline and the time point of every 8 weeks in first 16 weeks, at the time point of every 12 weeks after first 16 weeks.
DoR	up to 2 years	DoR is the time from the date of first detection of objective response (which is subsequently confirmed) until the date of objective radiographic disease progression.
rPFS	up to 2 years	rPFS is the time from the date of first dose until the date of objective radiographic disease progression or death (by any cause in the absence of progression) per RECIST v1.1 and PCWG3 criteria.
Time to next skeletal-related event	up to 2 years	The definition is the time from the date of first dose until the date of next skeletal-related event. Skeletal-related events include radiotherapy or surgery to the bone, pathological bone fracture, spinal cord compression, or changing anti-tumor treatment in order to relieve bone pain.
OS	up to 2 years	OS is the time from the date of first dose until the date of death by any cause.
Percentage of participants who experience an adverse event [Safety and Tolerability]	From the time of informed consent provided to 30 days after the last dose of study therapy	An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Percentage of participants who experience an adverse event and discontinue study drug due to an AE.

Trial Locations

Locations (1)

Fudan Cancer Hospital; 🇨🇳 Shanghai, Shanghai, China